3,6-Dichloropyrazine-2-carbonitrile

3,6-Dichloropyrazine-2-carbonitrile (CAS 356783-16-9) is a pharmaceutical-grade intermediate supplied by Hunan HuaTeng Pharmaceutical Co., Ltd. for use in the synthesis of Favipiravir, the antiviral (also known as T-705/Avigan) with activity against a range of RNA viruses that was studied in China as an experimental COVID-19 treatment. The supplier sources rather than manufactures the compound and markets it to North America, Central/South America, Western Europe, Eastern Europe, and the Middle East.